Ryan Confer, President and Chief Executive Officer at Genprex, sat down with the Marathon Money podcast to discuss the Company’s pipeline of gene therapies for cancer and diabetes. Watch the interview here: https://www.youtube.com/watch?v=blIpam7eBTc
Original article: Genprex – Developing Novel Gene Therapies in Cancer with Tumor Suppressor Genes and Diabetes Converting Alpha Cells into Beta Cells to Produce Insulin (CEO CFO Magazine)
Company’s CEO and CFO Highlights its Cutting-Edge Gene Therapy Programs AUSTIN, Texas — (Sept. 23, 2024) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company’s President, Chief Executive Officer and Chief Financial Officer, Ryan Confer, was featured in […]
Genprex, a clinical-stage gene therapy company, has recently released groundbreaking data from a non-human primate study evaluating a novel gene therapy to treat Type 1 diabetes.
With results of an animal study published in February 2023, Genprex aims to add credibility to another genome editing approach in the hunt for a functional cure to T1D.
How one company seeks to provide hope to cancer patients through more effective treatments.
Genprex's President and CEO, Rodney Varner, sits down with CEO/CFO Magazine to talk about Genprex, how it is reprogramming the course of cancer and diabetes and key catalysts in the next 6-12 months.
An experimental gene therapy developed by Texas biotech Genprex will be paired with AstraZeneca’s Tagrisso and Merck & Co’s Keytruda – both leading their respective drug classes in the treatment of non-small cell lung cancer (NSCLC).
Companies are optimizing nonviral delivery methods for commercial use
Austin startup a ripe M&A target for big pharma, one expert says